Provectus Biopharmaceuticals Announces Acceptance of PV-10(R) Melanoma Abstract for Oral Presentation at Melanoma Bridge 2020

Source :: GlobeNewswire. November 12, 2020
Publication Year :: 2020
Abstract: KNOXVILLE, TN, Nov 12, 2020 (GLOBE NEWSWIRE via COMTEX) -- Provectus (OTCQB: PVCT) today announced that data from the Company's ongoing Phase 1b/2 study of autolytic cancer immunotherapy PV-10, an [...]

Subjects :: Cancer treatment -- Forecasts and trends
Biopharmaceuticals -- Forecasts and trends
Immunotherapy -- Forecasts and trends
Pembrolizumab -- Forecasts and trends
Melanoma -- Development and progression
Market trend/market analysis
Banking, finance and accounting industries
Business
Keytruda (Medication)

Tools